Category:

Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend a Roche arthritis drug to tackle that rampage...Roche’s blockbuster Actemra, first approved by the U.S. FDA in 2010 for rheumatoid arthritis, can now be used to treat serious coronavirus patients with lung damage, China’s National Health Commission said in its updated treatment guidelines for COVID-19...READ MORE

Melinta Therapeutics, one of the few companies to recently bring a new antibiotic to market, filed for bankruptcy at the end of December. This news comes less than a year after another antibiotic developer, Achaogen, did the same thing...`More than 90% of antibiotics in the pipeline today are being developed by small companies like these, not by the pharmaceutical giants that once dominated the field. And with antibiotic prices low and profit margins narrow, many small companies just can’t stay afloat...just when the world needs more novel weapons in the fight against resistant pathogens, there are far too few in the pipeline. And although there are real scientific challenges in finding new antibiotics, the big drug companies have largely abandoned the field due to the low return on investment...READ MORE

With greater patient access to CBD, pharmacists will need to be prepared to address potential drug interactions to help patients use these products safely. The FDA has issued numerous warning letters instructing various manufacturers to halt production of OTC CBD products since 2016...Regarding interactions, in vitro studies have illustrated multiple potential drug interactions for CBD. The lack of standardized products somewhat limits the ability to make definitive statements from available research, but there is evidence that CBD is an inhibitor of many CYP450 enzymes including 2D6, 3A4, and 3A5, as well as a potent p-glycoprotein inhibitor...Research also suggests CBD use enhances the effect of opiates, and exhibits other interactions with barbiturates, fluoxetine, sedatives, and antihistamines, as well as having synergistic effects with alcohol...READ MORE

Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

Despite increased access to naloxone, many individuals in rural communities continue to face barriers to obtaining the medication…However, informed pharmacists can serve as an educational resource, even if their pharmacies do not have the medication in stock...Ongoing efforts to expand prescribing methods through the United States have helped to improve naloxone accessibility. In Georgia, specifically, a standing order decrees that any individual may obtain naloxone from a licensed pharmacy without a prescription. Despite the standing order, pharmacies have been slow to adopt stocking naloxone and dispensing the medication…READ MORE

Laura Joszt for The American Journal of Managed Care®. Here are the top 5 articles for the month of November.

Laura Joszt, Managing Editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network

Providers are making an increasing number of mistakes selecting the wrong medication for patients on their computer screens or tablets, according to the Institute for Safe Medication Practices ...The problem is that physicians and other providers select the wrong medication after entering the first few letters of the drug name into their technology screens, said the institute, which released its list of the top 10 most persistent medication errors and hazards it uncovered in 2019...READ MORE

Laura Joszt, Managing Editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network

Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.